Blue Earth Therapeutics is highlighting results from a preclinical study evaluating the efficacy of actinium-225 (Ac-225) rhPSMA-10.1 compared with lutetium (Lu-177) rhPSMA-10.1 for the treatment of prostate cancer.
The results were presented at the European Association of Nuclear Medicine (EANM23) in Vienna and showed that both Ac-225 rhPSMA-10.1 and Lu-177 rhPSMA-10.1 offered excellent prostate-specific membrane antigen binding, high cellular internalization, and similar lipophilicity, the company said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
